Clinical Trial

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

Study acronym: TranspoCART19
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are: Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational medicinal product and will be followed for 36 months.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-04-19; most recent amendment 2026-04-13.
Trial Details
NCT Number NCT06378190
Lead Sponsor Instituto de Investigación Biomédica de Salamanca
Collaborators: Spanish Clinical Research Network - SCReN, Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Fundación para la Investigación Biomédica del Hospital 12 de Octubre
Conditions Refractory B-Cell Lymphoma, B-cell Lymphoma Recurrent
Enrollment 27 participants
Start Date 2024-03-11
Primary Completion 2029-07 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-16